Adding Abemaciclib Offers Good Outcomes in Pre-/Perimenopausal Breast Cancer

Dave LevitanJun 5, 2018The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients.

Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news